In this commentary on Wang, Wu, Xia, and colleagues, Clinical Translational Medicine, 2022, we sum up and discuss recent evidence on the regulation and relevance of the transcription factor c‐FOS in diffuse large B cell lymphoma cells that are treated with epigenetic erasers of the histone deacetylase inhibitor family. Here, FOS is linked to diffuse large B-cell lymphoma.